Australian biotech market today 14.04.09
Tuesday, 14 April, 2009
The overall healthcare index was up on today’s trading at 2.30pm, following the trend of the rest of the indices. The All Ordinaries is up 2.5 per cent.
Cellestis (ASX:CST) is up 19c to $2.55 on the news that its TB diagnostic QuantiFERON-TB Gold In-Tube has received regulatory approval in Japan.
ChemGenex (ASX:CXS) is continuing to enjoy gains after announcing it had raised $10 million in secondary financing last week, up 4c to 46c.
Acrux (ASX:ACR) is up 2c to 65c, as is Biota (ASX:BTA) to 66c. Mesoblast (ASX:MSB) is up 5c to 85c.
Cochlear (ASX:COH) is up 68c, CSL (ASX:CSL) is down 11c and ResMed (ASX:RMD) is up 4c.
Pharmaxis (ASX:PXS) is down a steep 13c to $2.02 on reasonable volumes, as is Novogen (ASX:NRT), down 13.5 per cent to 48c. QRxPharma (ASX:QRX) is up 4c to 32c.
Progen (ASX:PGL) is up 3.8 per cent to 95c while Probiotec (ASX:PBP) is again enjoying healthy rises, up 6.2 per cent to $1.89.
Living Cell Technologies (ASX:LCT) is down 3.5c to 12c, while there has been some rare movement with LabTech Systems (ASX:LBT), up a cent to 14.5.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
